Evolution of hepatitis B serological markers in HIV coinfected patients: a case study

Toscano, Ana Luiza de Castro Conde; Corrêa, Maria Cássia Mendes

doi:10.1590/s1518-8787.2017051006693

Cited by 11 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared to other cohorts of HBV/HIV co-infected individuals, HBsAg clearance and anti-HBs seroconversion rates that we observed are lower [13–15]. The large proportion of individuals taking 3TC of FTC only for a long period could partly explain this finding.…”

Section: Discussioncontrasting

confidence: 51%

“…Long-term virological suppression of HBV replication represents the main endpoint of current HBV therapy, while HBsAg clearance is considered an optimal endpoint [11–12]. Functional cure of chronic HBV infection, defined as HBsAg loss, followed by the acquisition of anti-hepatitis B surface antibody (Anti-HBs), is a rare event: various studies have reported HBsAg seroclearance rates ranging from 1.7 to 2.6/100 patient-years in HBV/HIV co-infected subjects undergoing different therapeutic strategies [13–15]. However, the number of participants, a short follow-up duration and the lack of real-life settings limit these data.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

Gantner¹,

Cotte²,

Allavena³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Introduction Achieving functional cure of chronic HBV infection (Hepatitis B surface antigen [HBsAg] clearance, eventually followed by acquisition of anti-hepatitis B surface antigen [Anti-HBs]) in individuals with HIV and HBV infections is a rare event. In this setting, factors related to HBV cure have not yet been fully characterized. Methods HIV-infected individuals with chronic HBV infection enrolled in the French Dat’AIDS cohort (NCT02898987), who started combined antiretroviral (cART)-anti-HBV treatment were retrospectively analyzed for HBsAg loss and Anti-HBs seroconversion. Results Overall, 1419 naïve-subjects received three different cART-anti-HBV treatment schedule: (1) 3TC or FTC only (n = 150), (2) TDF with or without 3TC or FTC (n = 489) and (3) 3TC or FTC as first line followed by adding/switching to TDF as second line (n = 780). Individuals were followed-up for a median of 89 months (IQR, 56–118). HBV-DNA was < 15 IU/mL in 91% of individuals at the end of the follow-up. Overall, 97 individuals cleared HBsAg (0.7/100 patient-years), of whom, 67 seroconverted for Anti-HBs (0.5/100 patient-years). A high CD4 nadir, a short delay between HBV diagnosis and treatment, a longer time on HBV therapy, an African origin and TDF-based therapy were independent predictors of HBsAg clearance (Probability of odds ratio [OR]>1, >95%) suggested by Bayesian analysis. Also, TDF-based regimen as first line (OR, 3.03) or second line (OR, 2.95) increased rates of HBsAg clearance compared to 3TC or FTC alone, with a 99% probability. Conclusions HBsAg clearance rate was low in HIV-HBV co-infected cART-anti-HBV treated individuals, but was slightly improved on TDF-based regimen.

show abstract

Section: Discussioncontrasting

confidence: 51%

Section: Introductionmentioning

confidence: 99%

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

Gantner¹,

Cotte²,

Allavena³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In studies of HIV-HBV co-infection up to 22% of participants lost HBsAg, depending on duration of follow up [36, 110–118] . A higher frequency of HBsAg loss has been associated with lower CD4+ T cell count prior to initiation of HBV-active ART [114, 115, 117] and a greater increase in CD4+ T-cells following ART [115, 118] but many of these studies were retrospective or didn’t include individuals with low CD4+ T-cells prior to ART.…”

Section: Natural History Of Hiv-hbv Co-infection In the Era Of Hbvmentioning

confidence: 99%

HIV-hepatitis B virus coinfection

Singh¹,

Crane

Audsley

et al. 2017

Aids

172

View full text Add to dashboard Cite

HIV infection has a significant impact on the natural history of chronic HBV infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared to HBV mono-infection. Widespread uptake and early initiation of HBV-active antiretroviral therapy (ART) has substantially improved the natural history of HIV-HBV co-infection but the prevalence of liver disease remains elevated in this population. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease and seroconversion in HIV-HBV co-infection in the era of HBV-active ART and the effects of HIV directly on liver disease. We also review novel therapeutics for the management of HBV with a particular emphasis on clinical strategies being developed for an HBV cure and an HIV cure and their impact on HIV-HBV co-infected individuals.

show abstract

“…The observed prevalence of HBeAg among HIV patients from this study is comparatively higher than the findings by Awoderu et al [26] in Lagos, where they observed a prevalence of 3.1% among HIV positive patients.This high prevalence of HBeAg is not unexpected as HIV/AIDS infection confers a state of immunosupresion on the host with resultant increased rate of replication of the HBV. Also, there is documented evidence of seroreversion of HBeAb to HBeAg among patients with HBV/HIV co-infection which could have accounted for the increased level of HBeAg [25]. Of importance also, is the fact that the HIV/HBV cohort have higher frequency of HBcIgM in comparison with the HBV mono-infected which is depicted in .…”

Section: Discussionmentioning

confidence: 96%

Comparative serologic profiles of hepatitis B Virus (HBV) between HIV/HBV co-infected and Hbv mono-infected patients in Ile-Ife, Nigeria

Osasona

Adewale-Fashoro

Olumade

et al. 2021

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

Introduction: Hepatitis B virus(HBV) infects about 2 billion people globally and accounts for mortality of about 800,000 from liver cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for 70% of Human Immunodeficiency Virus (HIV) global burden. HIV/HBV coinfection results in early development of HBV complications, alterations of serological biomarkers of HBV. Methods : Two hundred and fifty patients with HIV/AIDS were screened for HBV and 20 (8%) were identified. Same number of HBV mono-infected individuals were recruited into the study and subsequently, HBV serological profiles which includes HBsAg, HBsAb, HBeAg, HBeAb,HBcAbIgM and HBcAbIgG were assayed using HBV ELISA kits.Result: Mean age of patients in the HBV/HIV cohort was 45.5 years while the HBV mono-infected infected cohort was 30.5 years. Majority of the HBV/HIV co-infected individuals were females (85%). Frequency of HBeAg among HIV/HBV co-infected cohort was 25% and 15% for HBV mono-infected , while the frequency of HBeAb was higher (60%) among cohort of HBV/HIV coinfected patients in comparison with the HBV mono-infected cohorts(50%). Two patients among the HIV/HBV co-infected cohort have the isolated anti-HBcAg serologic pattern. Conclusion:The study broadened the available evidence of comparative serologic profiles of Hepatitis B virus between cohorts of HBV/HIV co-infected individuals and HBV mono-infected patients in Nigeria.

show abstract

Evolution of hepatitis B serological markers in HIV coinfected patients: a case study

Cited by 11 publications

References 25 publications

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

HIV-hepatitis B virus coinfection

Comparative serologic profiles of hepatitis B Virus (HBV) between HIV/HBV co-infected and Hbv mono-infected patients in Ile-Ife, Nigeria

Contact Info

Product

Resources

About